Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort

Experimental Hematology & Oncology - Tập 3 - Trang 1-6 - 2014
Ashwin Sridharan1, Rishi Jain1, Marcus A Bachhuber2,3,4, Yiting Yu5, KH Ramesh6, Krishna Gundabolu7, Ellen W Friedman7, Amit K Verma8
1Department of Medicine, Albert Einstein College of Medicine, Bronx, USA
2Philadelphia Veterans Affairs Medical Center, , Philadelphia, USA
3Robert Wood Johnson Foundation Clinical Scholars Program, Univeristy of Pennsylvania, Philadelphia, USA
4Leonard Davis Insititute of Health Economics, University of Pennsylvania, Philadelphia, USA
5Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, USA
6Department of Pathology, Albert Einstein College of Medicine, Bronx, USA
7Department of Hematology, Albert Einstein College of Medicine, Bronx, USA
8Division of Oncology, Albert Einstein College of Medicine, Bronx, USA

Tóm tắt

Little is known about the epidemiology of MDS in minority populations. The IPSS and newly released IPSS-R are important clinical tools in prognostication of patients with MDS. Therefore, we conducted a retrospective epidemiological analysis of MDS in an ethnically diverse cohort of patients. Demographics, disease characteristics, and survival were determined in 161 patients seen at Montefiore Medical Center from 1997 to 2011. We observed that Hispanics presented at a younger age than blacks and whites (68 vs. 73.7 vs. 75.6 years); this difference was significant (p = 0.01). A trend towards greater prevalence of thrombocytopenia in Hispanics was observed, but this was not significant (p = 0.08). No other differences between the groups were observed. Overall median survival after diagnosis was the highest among Hispanics (8.6 years) followed by blacks (6.2 years) and Caucasians (3.7). Adjusted hazard ratios however did not show significant differences in risk of death between the groups. The IPSS-R showed slightly better discrimination when compared to the IPSS in this cohort (Somers Dxy 0.39 vs. 0.35, respectively) but observed survival more was more closely approximated by IPSS than by IPSS-R. Our study highlights the possibility of ethnic differences in the presentation of MDS and raises questions regarding which prognostic system is more predictive in this population.

Tài liệu tham khảo

Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 2009,361(19):1872–1885. 10.1056/NEJMra0902908 Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976,33(4):451–458. 10.1111/j.1365-2141.1976.tb03563.x Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997,89(6):2079–2088. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrect AA, Germing U, Hasse D: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012,120(12):2454–2465. 10.1182/blood-2012-03-420489 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfied CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009,114(5):937–951. 10.1182/blood-2009-03-209262 Keng MK, Sekeres MA: The race for survival in myelodysplastic syndromes. Leuk Lymphoma 2013,54(2):219–220. 10.3109/10428194.2012.726724 Ma X, Does M, Raza A, Mayne ST: Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007,109(8):1536–1542. 10.1002/cncr.22570 Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF: Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008,112(1):45–52. 10.1182/blood-2008-01-134858 Zandberg DP, Hendrick F, Vannorsdall E, Bierenbaum J, Tidwell ML, Ning Y, Zhao XF, Davidoff AJ, Baer MR: Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience. Leuk Lymphoma 2013,54(2):304–309. 10.3109/10428194.2012.710904 Ballen KK, Klein JP, Pedersen TL, Bhatla D, Duerst R, Kurtzberg J, Lazarus HM, LeMaistre CF, McCarthy P, Mehta P, Palmer J, Setterholm M, Wingard JR, Joffe S, Parsons SK, Switzer GE, Lee SJ, Rizzo JD, Majhail NS: Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2012,18(6):903–912. 10.1016/j.bbmt.2011.10.040 Komrokji R: Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk Res 2006,30(9):1067–1068. 10.1016/j.leukres.2006.04.004 Matsuda A, Germing U, Jinnai I, Araseki K, Kuendgen A, Strupp C, Iwanaga M, Miyazaki Y, Hata T, Bessho M, Gattermann N, Tomonaga M: Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromes. Leuk Res 2010,34(8):974–980. 10.1016/j.leukres.2009.11.015 Magalhaes SM, Heredia FF, Fernandes LC, Almeida PJ, Sousa JC, Souza GF, Pinheiro RF: Beyond race-related disparities: is myelodysplastic syndrome the same everywhere? Leuk Lymphoma 2013,54(7):1564–1566. 10.3109/10428194.2012.749404 Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, Seo EJ, Lee KH: Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003,17(2):305–313. 10.1038/sj.leu.2402798 Newson R: Confidence intervals for rank statistics: Somers' D and extensions. The Strata Journal 2006,6(3):1–25. Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A: Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol 2013,88(8):690–693. 10.1002/ajh.23477